Related Experiment Videos
Thromboxane does not mediate pulmonary vascular response to monocrotaline pyrrole
The American Journal of Physiology
|April 1, 1987
Summary
Thromboxane (Tx) does not appear to play a role in monocrotaline pyrrole (MCTP)-induced pulmonary hypertension in rats. Blocking Tx synthesis or action did not prevent lung damage or right ventricular hypertrophy in this animal model.
Area of Science:
- Pulmonary Hypertension Research
- Cardiovascular Pharmacology
- Toxicology
Background:
- Monocrotaline pyrrole (MCTP) is a known inducer of pulmonary hypertension and right ventricular hypertrophy in rat models.
- Thromboxane (Tx) is a vasoactive mediator implicated in various cardiovascular conditions, including pulmonary hypertension.
Purpose of the Study:
- To investigate the potential involvement of thromboxane (Tx) in the pathogenesis of MCTP-induced pulmonary hypertension.
- To determine if inhibiting Tx synthesis or blocking its action can mitigate the adverse cardiopulmonary effects of MCTP.
Main Methods:
- Pharmacological inhibition of Tx synthesis using ibuprofen (cyclooxygenase inhibitor) and dazmegrel (Tx synthetase inhibitor).
- Administration of a Tx receptor antagonist (L-640,035).
- Assessment of MCTP-induced lung weight, right ventricular hypertrophy, and broncho-pulmonary lavage fluid markers in rats.
Main Results:
- Ibuprofen and dazmegrel failed to attenuate MCTP-induced lung weight gain and right ventricular hypertrophy.
- Tx inhibition did not reduce markers of lung injury or vascular leak in MCTP-treated rats.
- Tx receptor antagonism also did not ameliorate the pulmonary hypertension or lung damage caused by MCTP.
Conclusions:
- Interference with thromboxane synthesis or action does not attenuate the toxic effects of MCTP in rats.
- These findings suggest that thromboxane is not essential for the development of MCTP-induced pulmonary hypertension and associated cardiopulmonary damage.